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Apoptosis-Inducing Ligand to Keratinocytes with a
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Michiyoshi Kouno1,2, Chenyan Lin1, Norman M. Schechter1, Don Siegel3, Xiaoping Yang1,
John T. Seykora1 and John R. Stanley1
We determined the feasibility of using an anti-desmoglein (Dsg) mAb, Px44, to deliver a biologically active protein
to keratinocytes. Recombinantly produced Px44–green fluorescent protein (GFP) injected into mice and skin
organ culture delivered GFP to the cell surface of keratinocytes. We replaced GFP with tumor necrosis factor–
related apoptosis-inducing ligand (TRAIL) to produce Px44-TRAIL. We chose TRAIL as a biological model because
it inhibits activated lymphocytes and causes apoptosis of hyperproliferative keratinocytes, features of various skin
diseases. Px44-TRAIL formed a trimer, the biologically active form of TRAIL. Standard assays of TRAIL activity
showed that Px44-TRAIL caused apoptosis of Jurkat cells and inhibited IFN-g production by activated CD4þ
T cells. Enzyme-linked immunoassay with Px44-TRAIL showed delivery of TRAIL to Dsg. Immunofluorescence with
Px44-TRAIL incubated on skin sections and cultured keratinocytes or injected into mouse skin, human
organ culture, or human xenografts detected TRAIL on keratinocytes. Px44-TRAIL caused apoptosis of the
hyperproliferative, but not differentiating, cultured keratinocytes through binding to Dsg3. Foldon, a small
trimerization domain, cloned into Px44-TRAIL maintained its stability and biological activity at 371 C for at least 48
hours. These data suggest that such targeted therapy is feasible and may be useful for hyperproliferative and
inflamed skin diseases.
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INTRODUCTION
In this study, we test the feasibility of targeting biologically
active proteins to keratinocytes. Such a strategy might be
useful in many scenarios depending on the agent delivered.
For example, one could consider delivery of agents that cause
local immunosuppression for epidermal diseases modulated
by activated lymphocytes (e.g., graft vs host disease, lichen
planus, discoid lupus erythematosus, and vitiligo), inhibitors of
cytokines that cause disease through actions on keratinocytes
(e.g., in psoriasis), enzymes to activate or inactivate drugs,
growth factor or growth-factor inhibitors, and laser targets.
Furthermore, agents that cause apoptosis of hyperproliferative
keratinocytes or melanocytes in the epidermis might be useful
in diseases such as psoriasis, actinic keratoses, skin, head
and neck squamous cell carcinoma (HNSCC), and lentigo
maligna.
Our hypothesis is that we can use nonpathogenic mono-
clonal anti-desmoglein (Dsg) single-chain variable fragment
(scFv) antibodies that we have cloned from pemphigus
patients (Payne et al., 2005) to deliver proteins to the epider-
mis. These scFvs are ideal agents for targeting molecules to
keratinocytes, which express Dsgs on their surface, for several
reasons. They are small (approximately 25 kD) single-chain
antibodies that contain only the antigen-binding site and
diffuse well through the tissue. They do not contain the
effector region of full-length antibodies, and therefore, they
will not elicit antibody-induced inflammation. They are
human and, in themselves, would not elicit an immune
reaction in most people. They are cloned and can be easily
used to make and produce recombinant molecules.
We chose one of these nonpathogenic anti-Dsg scFvs to
show proof of principle of our hypothesis. First, we used it to
deliver a marker protein, enhanced green fluorescent protein
(GFP), to the surface of keratinocytes in normal epidermis.
Once we showed that was feasible, we then used it to deliver
biologically active tumor necrosis factor–related apoptosis-
inducing ligand (TRAIL). We chose TRAIL as a biological
model because it causes apoptosis of hyperproliferative
keratinocytes and inhibits activated lymphocytes, features of
many of the skin diseases discussed above.
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The homotrimeric form of TRAIL has proapoptotic activity,
whereas the dimer and monomer forms are inactive (Trabzuni
et al., 2000). TRAIL is known as a selective anti-tumor agent,
which induces apoptosis of various malignant hyperpro-
liferative cells, including melanocytes (Thomas and Hersey,
1998; Zhang et al., 1999) and keratinocytes (Kothny-Wilkes
et al., 1998; Leverkus et al., 2000; Basile et al., 2001; Qin
et al., 2001; Jansen et al., 2003), usually without toxicity, or
with much less toxicity, for normal cells, including
keratinocytes (Kothny-Wilkes et al., 1998; Ashkenazi et al.,
1999; Leverkus et al., 2000; Basile et al., 2001; Qin et al.,
2001; Jansen et al., 2003). Thus, TRAIL may be a potential
therapeutic agent with a selective inhibitory effect for skin
diseases with hyperproliferative keratinocytes or melanocytes.
Supporting this notion, in a mouse model of chemical-induced
skin carcinogenesis, forced expression of TRAIL on keratino-
cytes (using a K14-TRAIL transgenic mouse) markedly
inhibited preneoplastic lesions and tumor formation
(Kedinger et al., 2011). Finally, in HNSCC, which highly
express Dsg 3 (Chen et al., 2007; Huang et al., 2010; Solassol
et al., 2010), TRAIL death receptors are expressed, although in
some cases they are downmodulated in metastases (Elrod
et al., 2010; Yoldas et al., 2011). In addition, many HNSCCs
are associated with oncogenic papilloma viruses and
keratinocytes, expressing papillomavirus-16 E7 oncogene,
and are susceptible to TRAIL-induced apoptosis (Basile
et al., 2001). Thus, targeted delivery of TRAIL to such
neoplasms may be therapeutic.
Finally, TRAIL is also shown to be an immunosuppressive
agent, which inhibits inflammation in several autoimmune
disease animal models, including rheumatoid arthritis
(Martinez-Lostao et al., 2010), autoimmune encephalomye-
litis (Hirata et al., 2005), and autoimmune thyroiditis (Wang
et al., 2009).
Delivering TRAIL to normal epidermis could potentially
establish a type of immunological privilege, as proposed for
its natural expression in the eye and at the maternal-fetal
interface (Phillips et al., 1999; Niederkorn, 2006). Such a
function might be useful in various diseases thought to be
possibly mediated by activated lymphocytes in epidermis, as
discussed above.
In these studies, we demonstrate that we can recombinantly
produce TRAIL linked to anti-Dsg scFv, that the TRAIL is
biologically active and stable, and that it can be delivered to
Dsg on the cell surface of keratinocytes in the epidermis.
RESULTS
Design of a baculovirus modular vector to clone and produce an
anti-Dsg scFv fusion protein to be used as an epidermal targeting
vehicle
Previously, we isolated, by antibody phage display, mono-
clonal anti-Dsg scFv antibodies from pemphigus patients.
Most of these antibodies, although they bound to Dsg
and the epidermis, were nonpathogenic. We used one of
these nonpathogenic anti-Dsg antibodies, Px44, to test the
feasibility of delivering a protein to the cell surface of
keratinocytes in epidermis. Px44 injected intraperitoneally
into mice localizes to multiple stratified squamous epithelial
surfaces and persists there for at least 5 days (Supplementary
Figure S1 online).
To use scFv for protein delivery, we designed a baculovirus
vector (Figure 1a) with two cassettes to produce a fusion
protein: one 50 with SfiI sites for a phage display-cloned scFv
(which typically has SfiI sites at both ends) and the other 30
with a NotI site that can be used to clone cDNA, PCR-
amplified with primers containing NotI sites, for essentially
any protein (see example in Figure 1b). We chose a baculo-
virus vector (used in insect cells) to allow eukaryotic post-
translational modification and folding to preserve
physiological function of the fused protein. In addition, the
vector encodes gp67, an extremely efficient signal peptide
that allows secretion of the recombinant protein into the
insect cell media for easy purification, and both a histidine
6 tag (for purification of encoded fusion protein on a nickel
or cobalt column) and a hemaggultinin (HA)-epitope tag on
the 30 end.
To determine whether Px44 can deliver a fused protein to
the epidermis, we used this vector to clone cDNA encoding
enhanced GFP (27 kD) to the 30 end of cDNA encoding Px44
(Figure 1a). The encoded fusion protein, called Px44GFP, was
produced in insect cell media then purified by metal-affinity
chromatography on a Talon (cobalt) column. Direct immuno-
fluorescence showed GFP bound to the cell surface of
epidermal keratinocytes after purified Px44GFP was injected
intradermally into normal human skin organ culture or
intravenously into an adult mouse (Figure 1c and d). These
results demonstrate that Px44 can be used to deliver a protein
to epidermal keratinocytes.
Biochemical and immunological characterization of Px44-mouse
(m) TRAIL
To investigate the feasibility of targeted drug delivery of a
biologically active protein by Px44, we substituted the extra-
cellular domain of mouse TRAIL (mTRAIL) for GFP in the
baculovirus vector (Figure 1a and b), then produced and
purified the Px44-mTRAIL by binding it to an anti-HA agarose
column and elution with excess HA peptide, because this gave
consistently better purity compared with metal-affinity chro-
matography. Coomassie Blue staining of SDS-PAGE of the
purified Px44-mTRAIL showed a single major band that
migrated slightly slower than the 53 kDa standard and that
stained with an anti-mTRAIL mAb on immunoblot (Figure 2a).
This apparent molecular weight was slightly larger than the
predicted molecular weight based on the amino-acid
sequence (54 kDa), perhaps due to N-glycosylation for which
there are 1–2 predicted sites. As TRAIL is biologically active as
a homotrimer, whereas its monomer or dimer is inactive, we
analyzed whether Px44-mTRAIL forms a homotrimer by size-
exclusion chromatography (Figure 2b). A major peak eluting at
a position somewhat ahead of IgG (150 kDa) is consistent with
a homotrimer of Px44-TRAIL monomers, each with a mass of
54 kDa. (The peaks at smaller molecular weight indicate
the 3-(N-morpholino)propanesulfonic acid buffer added to the
sample before analysis (indicating the internal volume of the
column) and the small peak eluting after the internal volume is
HA peptide (used to purify the fusion protein) that was not
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completely removed by dialysis. These results show that the
normal spontaneous homotrimer formation of TRAIL can
occur when it is fused to the Px44 scFv, resulting in a trimer
of the fusion protein.
Further, we determined whether the anti-Dsg scFv in the
fusion protein retained its antigenic specificity. Dsg 3 ELISA
developed with anti-HA and anti-mTRAIL antibody demon-
strated that Px44-mTRAIL retained the antigenic specificity of
the Px44 scFv antibody, and that Px44 binds the fused protein
to the target antigen, Dsg3 (Figure 2c).
TRAIL in the Px44-mTRAIL fusion protein is biologically active
To examine the biological activity of the TRAIL in the fused
mTRAIL protein, we used a standard assay of TRAIL activity,
its ability to cause apoptosis of Jurkat cells, which are a
hyperproliferative T-lymphocyte leukemia cell line (Figure 3a).
Px44-mTRAIL, recombinant mTRAIL (rmTRAIL, positive con-
trol) or phosphate-buffered saline (negative control) was
incubated for 16 hours with Jurkat cells in suspension culture.
Apoptotic cells were quantitated by flow cytometry after
staining with anti-annexin-V for early apoptosis (dying cells)
and propidium iodide for late apoptosis (dead cells). TRAIL
in Px44-mTRAIL needed an anti-HA cross-linking to
show activity consistently, probably because it helped to
aggregate the receptors (also see below). Px44-mTRAIL
(with anti-HA cross-linking) had similar activities to about
twice the molar amount of recombinant TRAIL (without
antibody cross-linking) with 36% and 32% dead and dying
cells, respectively.
TRAIL has also been reported to inhibit activated T cells
by decreasing cytokine production (e.g., IFN-g), but not
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Figure 1. Recombinant production and immunofluorescent analysis of anti-desmoglein (Dsg) single-chain variable fragment (scFv) fused to green fluorescent
protein (GFP). (a) Modular baculovirus vector with cDNA encoding scFv in an SfiI restriction site and enhanced GFP (EGFP) in a NotI restriction site. cDNA
encoding histidine 6 (H6) and a hemaggultinin (HA)-epitope tag are on the 30 end. The polyhedron promoter is a strong promoter in insect cells. The gp67 signal
peptide allows secretion of the translated fusion protein. (b) PCR strategy for amplifying cDNA for TRAIL (or any other protein) to insert in the NotI site of the vector.
(c) The Px44GFP fusion protein as injected intradermally into human skin in organ culture, which was harvested 18 hours after injection and microscopically
examined for GFP fluorescence. GFP is present on the cell surface of keratinocytes. Marker¼ 12mm. (d) The Px44GFP fusion protein was injected in the tail vein
of a mouse that was killed 6 hours later. The ear (shown here en face) shows GFP fluorescence on the cell surface of keratinocytes. Marker¼ 10mm.
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Figure 2. Biochemical and immunological characterization of Px44–mouse
tumor necrosis factor–related apoptosis-inducing ligand (mTRAIL).
(a) Western blotting with anti-mTRAIL antibody (left panel), and Coomassie
Blue staining (right panel) of SDS-PAGE of Px44-mTRAIL and commercial
recombinant mTRAIL (rmTRAIL) protein show bands of expected approximate
molecular weights. (b) Size-exclusion chromatography of Px44-mTRAIL. The
peak slightly larger than the 150 kDa (IgG) marker indicates trimer formation of
Px44-mTRAIL. (c) Desmoglein 3 (Dsg3) ELISA by using anti-hemaggultinin
(HA) antibody (left panel) and anti-mTRAIL antibody (right panel) shows
binding of Px44-mTRAIL to Dsg3. Crbn Anhyd, carbonic anhydride; MOPS,
3-(N-morpholino)propanesulfonic acid; Trnfn, transferrin.
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necessarily by apoptosis (Lunemann et al., 2002). To test
Px44-mTRAIL for such activity, we showed that it decreased
IFN-g expression by living activated mouse CD4þT cells
(Figure 3b).
These results indicated that the fused TRAIL protein in
Px44-mTRAIL maintained its biological activity both in
apoptosis of hyperproliferative cells and in the inhibition of
activated T cells.
Px44-mTRAIL binds to keratinocytes and causes Dsg3-specific
apoptosis of cultured proliferating, but not more differentiating,
keratinocytes
TRAIL is known to trigger apoptosis in undifferentiated,
hyperproliferative cultured keratinocytes, but not in differen-
tiating keratinocytes (Jansen et al., 2003). To test whether the
Px44-mTRAIL fusion protein could cause antigen-specific
apoptosis of proliferating keratinocytes by binding to Dsg,
we first tested binding of Px44-mTRAIL to cultured normal
human epidermal keratinocytes. For a control, we produced
AM3-13-mTRAIL, in which the irrelevant scFv antibody AM3-
13 was linked to mTRAIL. To produce the vector encoding this
fusion protein, we replaced the cDNA encoding Px44 with
that encoding AM3-13 in the SfiI site of the baculovirus vector
described above (Figure 1a). As determined by immunofluor-
escence with antibodies to the HA-epitope tag, Px44-mTRAIL,
but not AM3-13-mTRAIL, bound to the cell surface of cultured
keratinocytes (Figure 4a). The binding of Px44-mTRAIL on
keratinocytes was also detected with an anti-mTRAIL
antibody. Therefore, Px44 can deliver the fused mTRAIL
protein to the specific target antigen on living keratinocytes.
To demonstrate antigen-specific apoptosis of proliferating
keratinocytes, we added Px44-mTRAIL (and AM3-13-mTRAIL
with equal TRAIL specific activity, as a negative control) to
undifferentiated human keratinocytes cultured in low calcium,
and then washed the cells. We then determined apoptosis of
keratinocytes by flow cytometry after another 16 hours of
culture. We found that Px44-mTRAIL resulted in about 47%
dead (propidium iodide–positive) and dying (annexin-V-posi-
tive, propidium iodide–negative) cells compared with 18%
AM3-13-TRAIL (Figure 4b, left, upper). To confirm the anti-
gen-specificity of the delivery of biologically active TRAIL to
the keratinocytes, we showed that soluble recombinant Dsg3
blocked the apoptosis of keratinocytes induced by Px44-
mTRAIL (Figure 4b, left, lower). These data demonstrate that
the Px44-mTRAIL binding to Dsg3 enhances its ability to
cause apoptosis of keratinocytes by binding it to the keratino-
cytes, allowing its effect after washout of the soluble molecule,
whereas the short incubation without binding (either from
AM3-13-mTRAIL or Px44-mTRAIL blocked from binding with
soluble Dsg3) is much less effective.
Finally, we examined the sensitivity of differentiating
keratinocytes cultured in high calcium (1.2 mM) for 48 hours
to Px44-mTRAIL-induced apoptosis (Figure 4b, right).
Although dead or dying cells (24%) due to differentiation
were observed, as expected, in differentiating keratinocytes
without any active reagent added, adding Px44-mTRAIL
hardly increased their number (27%). Thus, unlike more
proliferative cells cultured in lower-calcium medium, the
differentiating, less-proliferative keratinocytes were resistant
to Px44-mTRAIL-induced apoptosis.
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Figure 3. Biological activity of mouse tumor necrosis factor–related apoptosis-inducing ligand (mTRAIL) fused to Px44 determined by flow cytometry. (a) Px44-
mTRAIL (with anti-hemaggultinin (HA) antibodies) induced apoptosis of Jurkat cells, as did recombinant mTRAIL (rmTRAIL). (b) Px44-mTRAIL (with anti-HA
antibodies) inhibited IFN-g production of living activated mouse CD4þ T cells. (Dead cells were gated out.) PBS, phosphate-buffered saline; PI, propidium iodide.
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Taken together, these results indicate that Px44-mTRAIL
binds to keratinocytes and causes apoptosis of cultured
hyperproliferative, but not more differentiating, keratinocytes.
Cloning and characterization of Px44 fused to human TRAIL and
stabilization of trimer formation and biological activity with
foldon
Ultimately, for human targeted therapy with TRAIL, we would
prefer human TRAIL fused to Px44. In addition, hTRAIL is
thought to be more potent than mTRAIL (Berg et al., 2007).
Finally, enforced trimerization with a potent trimerization
domain is thought to preserve stability and activity of TRAIL.
Therefore, we used the baculovirus cloning vector (Figure 1a
and b) to substitute PCR-amplified cDNA encoding hTRAIL for
the cDNA encoding mTRAIL to produce a vector encoding
Px44-hTRAIL. We also added a small potent trimerization
domain called foldon, (Meier et al., 2004) encoded within the
PCR primers to produce Px44-foldon-hTRAIL. We tested the
fusion protein produced by these constructs for biological
activity, stability at 371C, and ability to diffuse from
the dermis to bind the cell surface of keratinocytes in intact
epidermis.
Incubation of Jurkat cells for 16 hours with Px44-hTRAIL at
1mg ml 1 (without preincubation at 371C) caused approxi-
mately 53% dead and dying cells (Figure 5a, ‘0-hour’ column,
bottom). Px44-foldon-hTRAIL was more potent under these
conditions causing approximately 78% dead and dying cells
(Figure 5a, ‘‘0-hour’’, top). Furthermore, Px44-hTRAIL lost
activity during preincubation at 371C before incubation with
Jurkat cells. After 16-hour preincubation, Px44-hTRAIL caused
approximately 40% dead and dying cells (down from 53%),
whereas preincubation of Px44-foldon-hTRAIL at 371C did
not cause loss of activity; it maintained its ability to cause
apoptosis in 80% of cells. Even after preincubation for 48
hours at 371C, Px44-foldon-hTRAIL maintained its ability to
cause apoptosis in approximately 80% of Jurkat cells
(Figure 5b, top row), whereas Px44-hTRAIL gradually further
lost that ability. However, using anti-HA to externally cross-
link Px44-hTRAIL fully restored its apoptotic ability to over
80% (Figure 5b, bottom row). These data suggest that Px44-
hTRAIL at 371C gradually loses its trimerization and, with that,
its ability to cross-link its receptor, but the addition of anti-HA
allows external cross-linking and activity restoration.
The greater stability of Px44-foldon-hTRAIL is confirmed by
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Figure 4. Target antigen–specific function of Px44–mouse tumor necrosis factor–related apoptosis-inducing ligand (mTRAIL). (a) Px44-mTRAIL bound to the
cell surface of normal human epidermal keratinocytes in low calcium (0.4mM) (left panel), whereas control fusion protein AM3-13-mTRAIL did not
(middle panel). Binding of Px44-mTRAIL was detected by anti-hemaggultinin (HA) antibody (left panel) and anti-mTRAIL antibody (right panel). (b) The normal
human epidermal keratinocytes in low calcium (0.4 mM) were treated with Px44-mTRAIL or AM3-13-mTRAIL. After 2 hours of incubation, cells were washed and
then cultured for a further 16 hours, and the cells were analyzed by flow cytometry for apoptosis. Increased cell death was seen in Px44-mTRAIL-treated
keratinocytes (upper left) compared with cells treated with AM3-13-mTRAIL. In the presence of recombinant desmoglein (rDsg3) during the 2-hour incubation
with fusion proteins, the effect of Px44-mTRAIL-HA treatment was inhibited (lower left). In high calcium (1.2mM), keratinocytes were resistant to Px44-mTRAIL-
induced apoptosis. PBS, phosphate-buffered saline; PI, propidium iodide.
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size-exclusion chromatography (Figure 5c), in which Px44-
foldon-hTRAIL maintains trimer formation even for 48 hours at
371C, but the trimer of Px44-hTRAIL is gradually lost.
Px44-mTRAIL binds to the cell surface of keratinocytes in normal
epidermis
Because biologically active Px44-TRAIL is a trimer and we
ultimately want to use it to deliver TRAIL to the epidermis, we
wanted to show that Px44-TRAIL could diffuse from the dermis
to the epidermis and bind to the keratinocyte cell surface.
First, we injected Px44-mTRAIL intradermally into neonatal
mouse back skin. At 2 hours after subcutaneous injection,
Px44-mTRAIL bound to the epidermal cell surface of basal and
hair follicle keratinocytes as detected by immunofluorescence
with anti-HA (Figure 6a).
To examine the binding of Px44-foldon-hTRAIL, we
injected it intradermally into human skin organ culture. At
2 hours after injection, Px44-foldon-hTRAIL bound to the
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PI, propidium iodide.
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keratinocyte cell surface, as detected by anti-HA antibodies
and anti-hTRAIL antibodies (Figure 6b). Px44-foldon-hTRAIL
also bound to the keratinocytes of human skin xenografts on
immunodeficient mice 1 hour after intradermal injection
(Figure 6c). Finally, we injected Px44-foldon-hTRAIL into
mouse back skin once then again in 16 hours. At 30 min after
the last injection, harvested skin was positive by anti-HA
immunofluorescence but negative by TUNEL staining (data
not shown). These results demonstrate that Px44-foldon-
hTRAIL can cross the basement membrane of normal human
skin to be delivered to the surface of keratinocytes but does
not cause apoptosis in normal epidermis.
DISCUSSION
In this study, we show that it is feasible to molecularly clone
and produce an anti-Dsg3 scFv linked as a fusion protein with
an indicator protein, GFP, or a biologically active protein,
TRAIL, and that the scFv targets the fused protein to the
keratinocyte cell surface in culture or in tissue.
TRAIL and agonist antibodies against its cell death receptors
have been, or are, in clinical trials for various cancers
(Abdulghani and El-Deiry, 2010). However, one major
problem is that the therapy is, in general, not targeted and
there may be some toxicity to normal organs, usually
liver, and especially at higher doses or with more active
TRAIL preparations. Some preclinical studies have
shown the feasibility of targeted therapy of TRAIL with
scFv antibodies to cancer-specific antigens or antigens
overexpressed in the neoplastic cells (Bremer et al., 2004,
2005; de Bruyn et al., 2010; Schneider et al., 2010). In these
studies, the targeted TRAIL showed greater activity in causing
apoptosis of tumor cells than untargeted TRAIL and also
showed a ‘‘bystander effect’’, i.e., it kills neighboring cells
that do not have the targeted antigen. It is thought that
‘‘attaching’’ TRAIL to a cell surface also increases its specific
activity. The unique aspect of our approach is to use a human
scFv to target normal tissue (epidermis) to prevent
inflammation or to target developing hyperproliferative
lesions in those tissue (e.g., actinic keratoses, early HNSCC,
psoriasis, and lentigo maligna) lesions. Adding credence to the
idea that cell-surface TRAIL might contribute to tumor
surveillance, a recent study showed that imiquimod and
IFN-a induce TRAIL expression on plasmacytoid dendritic
cells, which then developed the ability to cause apoptosis
of melanoma cells (Kalb et al., 2012). It was proposed that
it is partially through this mechanism that imiquimod
can be therapeutically active against actinic keratoses and
skin cancer.
Although detailed analysis of the effects of Px44-TRAIL in
in vivo disease models was beyond the scope of this report,
we did test its activity in a K14-activated Fyn mouse model of
actinic keratoses and early squamous cell carcinoma (Zhao
et al., 2009). In this model, we could show in two experiments
that Px44-mTRAIL and Px44-foldon-hTRAIL caused apoptosis
in such neoplasms (Supplementary Figure S2 online), confirm-
ing the ideas above.
Another unique aspect of our study is that the modular
vector we developed can fuse essentially any protein to an
anti-Dsg scFv to deliver it to the epidermis. By using TRAIL or
other proteins that inhibit activated lymphocytes, we can
potentially suppress certain immunological reactions that
cause the epidermal disease.
There are potential problems with targeted therapy of TRAIL
to the epidermis that will have to be addressed in future
studies. For example, even though the anti-Dsg3 scFv and
TRAIL used here are human, there could be an immune
response against the linker or foldon. In the case of foldon,
other less-antigenic trimerization domains such as leucine or
isoleucine zippers could be substituted (Abdulghani and
El-Deiry, 2010). Another issue is that, although soluble TRAIL
usually does not affect normal epidermis, targeted TRAIL
might. However, our initial studies in mouse epidermis
suggest that, at least under certain conditions, it does not. In
addition, K14-TRAIL transgenic mice that overexpress TRAIL
in the epidermis do not show toxicity of normal epidermis
(Kedinger et al., 2011). However, with each particular TRAIL
delivery method, more extensive studies would need to
address this issue. Finally, how fast the targeted TRAIL turns
over in the skin (either through keratinocyte shedding or
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Figure 6. Px44–mouse tumor necrosis factor–related apoptosis-inducing
ligand (mTRAIL) and Px44–foldon–human TRAIL (hTRAIL) diffuse across the
basement membrane of mouse and human epidermis to bind to the cell
surface of keratinocytes. (a) Px44-mTRAIL injected into neonatal mice binds to
the cell surface of hair follicle and basal keratinocytes as detected by anti-
hemaggultinin (HA) immunofluorescence. Area in white box is shown closer
up to the right of its image. Marker¼ 10 mm. (b) Px44-foldon-hTRAIL injected
intradermally into human skin in organ culture binds to the cell surface of
keratinocytes as detected by immunofluorescence with anti-HA and anti-
hTRAIL. Marker¼ 10mm. (c) Px44-foldon-hTRAIL injected intradermally into
human skin xenografts on mice binds to the cell surface of keratinocytes as
detected by immunofluorescence with anti-HA antibodies. Area in white box is
shown closer up to the right of its image. Marker¼ 10mm. PBS, phosphate-
buffered saline.
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cellular internalization) will affect its therapeutic efficacy in
different situations. In treating tumors, TRAIL, although
beneficial in killing proliferating cells, might be detrimental
if it downregulates the host immune response. However, these
issues have to be determined empirically; for example, it may
only require short contact with hyperproliferative cells to
eliminate that pool. However, it may require more sustained
contact to affect activated lymphocytes if they are continually
renewed.
In any case, we show here that targeting proteins to the
epidermis with an anti-Dsg3 scFv, derived from a human PV
patient, is practical. This work establishes the practicality and
basis for testing this fusion protein, as well as others targeted to
keratinocytes in various immunological skin diseases and
precancerous and cancerous lesions.
MATERIALS AND METHODS
Design of baculovirus vector for producing fusion proteins
We modified the cloning vector pAcGP67 Baculovirus Transfer
Vector (BD Biosciences, San Jose, CA) to express and secrete scFv
fusion proteins in insect cells (Figure 1a) (Supplementary Materials
and Methods online have further details).
Production and purification of recombinant proteins
Chimeric protein in the culture supernatant of a baculovirus expres-
sion system in insect cells was bound to anti-HA agaraose beads and
then eluted with excess HA peptide.
ELISA
A Dsg3 ELISA kit (MBL, Woburn, MA) was used.
Cell culture
Jurkat cells were cultured in RPMI 1640 in 96-well plates.
Normal human epidermal keratinocytes obtained from neonatal
foreskins were cultured in Defined K-SFM (Life Technologies, Grand
Island, NY).
Mouse CD4þ T cells were enriched from splenocytes of C57BL/6
mice by positive selection using the MACS cell-separation system
(Miltenyi Biotec, Berisch Gladbach, Germany). For Th1-skewed
culture conditions, cells were cultured with anti-CD3, anti-CD28,
anti-IL-4, and IL-12.
Flow cytometry
Analysis of apoptosis of Jurkat cells and normal human epidermal
keratinocyte used the FITC-annexin-V Apoptosis Detection Kit I (BD
Biosciences). For analysis of normal human epidermal keratinocyte,
both floating and adherent cells were harvested. For intracellular
cytokine staining, mouse CD4þ T cells were treated with phorbol
12-myristate 13-acetate, ionomycin, and brefeldin A (Sigma, St Louis,
MO) and stained with FITC-anti mouse CD4 (Biolegend, San Diego,
CA) and PE-anti mouse IFN-g (Biolegend).
Immunohistochemistry
Immunofluorescence was performed as previously described (Payne
et al., 2005).
Immunoblot
General procedures were as previously described (Ishii et al., 2008).
Human skin organ culture injection
Five-mm-square pieces of normal skin were injected intradermally
with 50ml of protein (1mg ml 1), then, after 2–18-hour culture, they
were harvested for immunofluorescence.
Protein injection into the mice
Chimeric proteins were injected intravenously or intradermally
and those that bound to the epidermis were detected by
immunofluorescence.
Size-exclusion chromatography
Samples of 100ml were analyzed on a Superose 12 HPLC column
(Bio-Rad, Hercules, CA).
Animals and human subjects
Approvals for animal protocols and for human subjects were obtained
from appropriate review boards at the University of Pennsylvania.
Only discarded, deidentified human material was used.
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